基于药物基因组学的决策支持预测用药依从性
一项前瞻性病例对照研究纳入536例患者,分析超过6000张涉及39种药物的电子处方,评估药物基因组学指导能否提高依从性。
要点
- 药物基因组学信息可预测用药依从性,高风险药物处方与低依从性相关。
- 提供药物基因组学指导未显著改善整体平均依从性。
- 临床可基于药物基因组学风险分层识别依从性差的高危患者。
核心结论
- 药物基因组学综合信息可预测用药依从性,高风险药物处方与低依从性相关。
研究设计与样本
- 前瞻性病例对照研究,病例组接受预先药物基因组学基因分型且结果可供医生在诊疗点使用,对照组未进行基因分型但由同一批医生治疗。
- 共纳入536例患者,分析超过6000张涉及39种具有可操作药物基因组学信息的药物的电子处方。
主要发现
- 药物基因组学指导的可及性未导致平均mPDC出现差异。
临床怎么用
- 临床可利用药物基因组学信息识别使用高风险药物且依从性可能较差的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Poor adherence is associated with worse disease outcomes. Pharmacogenomics provides a possible intervention to address adherence. We hypothesized that pharmacogenomic-informed care could increase adherence. Patients in a prospective case-control study underwent preemptive pharmacogenomic genotyping with results available for provider use at the point of care; controls (not genotyped) were treated by the same providers. Over 6,000 e-prescriptions for 39 medications with actionable pharmacogenomic information were analyzed. Composite adherence, measured by modified proportion of days covered (mPDC), was compared between cases/controls and genomically concordant vs. genomically higher-risk medications. Overall, 536 patients were included. No difference in mean mPDC was observed due to availability of pharmacogenomic guidance. However, case patients prescribed high-risk pharmacogenomic medications were more than twice as likely to have low mPDC for these medications compared with genomically concordant prescriptions (odds ratio = 2.4 (1.03-5.74), P < 0.05). This study is the first to show that composite pharmacogenomic information predicts adherence.
引用
- Christian C, Borden BA, Danahey K, et al. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020. PMID: 32236960. doi:10.1002/cpt.1838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。